


## CLAIMS

## 1. A compound of formula I:

5



## FORMULA I

10 wherein substituents R1 - R7 and X are defined as follows:

R1, R2, R3 and R4 each independently are selected from hydrogen, halogen (selected from F, Cl, Br or I), a linear or branched alkyl group containing from 1 to 10 carbon atoms and optionally substituted with one or more heteroatoms such as halogen (selected from F, Cl, Br or I), oxygen, and nitrogen, the latter optionally in the form of a pendant basic nitrogen functionality, as well as trifluoromethyl, C<sub>1-6</sub>alkyloxy, amino, C<sub>1-6</sub>alkylamino, di(C<sub>1-6</sub>alkyl)amino, carboxyl, cyano, nitro, formyl, hydroxy, and CO-R, COO-R, CONH-R, SO<sub>2</sub>-R, and SO<sub>2</sub>NH-R wherein R is a linear or branched alkyl group containing from 1 to 10 carbon atoms and optionally substituted with at least one heteroatom, notably a halogen (selected from F, Cl, Br or I), oxygen, and nitrogen, the latter optionally in the form of a pendant basic nitrogen functionality.

R5 is one of the following:

- (i) hydrogen, or
- 25 (ii) a linear or branched alkyl group containing from 1 to 10 carbon atoms and optionally substituted with one or more heteroatoms such as halogen (selected from

F, Cl, Br or I), oxygen, and nitrogen, the latter optionally in the form of a pendant basic nitrogen functionality, or

(iii) CO-R8 or COOR8 or CONHR8 or SO2R8 wherein R8 may be

5 - a linear or branched alkyl group containing from 1 to 10 carbon atoms and optionally substituted with one or more heteroatoms such as halogen (selected from F, Cl, Br or I), oxygen, and nitrogen, the latter optionally in the form of a pendant basic nitrogen functionality, or

10 - an aryl group such as phenyl or a substituted variant thereof bearing any combination, at any one ring position, of one or more substituents such as halogen (selected from F, Cl, Br or I), alkyl groups containing from 1 to 10 carbon atoms and optionally substituted with one or more heteroatoms such as halogen (selected from F, Cl, Br or I), oxygen, and nitrogen, the latter optionally in the form of a pendant basic nitrogen functionality; as well as trifluoromethyl, C<sub>1-6</sub>alkyloxy, carboxyl, cyano, nitro, formyl, hydroxy, C<sub>1-6</sub>alkylamino, di(C<sub>1-6</sub>alkyl)amino, and amino, the latter 15 nitrogen substituents optionally in the form of a pendant basic nitrogen functionality; as well as CO-R, COO-R, CONH-R, SO2-R, and SO2NH-R wherein R is a linear or branched alkyl group containing from 1 to 10 carbon atoms and optionally substituted with at least one heteroatom, notably a halogen (selected from F, Cl, Br or I), oxygen, and nitrogen, the latter optionally in the form of a pendant basic nitrogen 20 functionality, or

25 - a heteroaryl group such as a pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, thienyl, thiazolyl, imidazolyl, pyrazolyl, pyrrolyl, furanyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, indolyl, benzimidazole, quinolinyl group, which may additionally bear any combination, at any one ring position, of one or more substituents such as halogen (selected from F, Cl, Br or I), alkyl groups containing from 1 to 10 carbon atoms and optionally substituted with one or more heteroatoms such as halogen (selected from F, Cl, Br or I), oxygen, and nitrogen, the latter optionally in the form of a pendant basic nitrogen functionality; as well as trifluoromethyl, C<sub>1-6</sub>alkyloxy, carboxyl, cyano, nitro, formyl, hydroxy, C<sub>1-6</sub>alkylamino, di(C<sub>1-6</sub>alkyl)amino, and amino, the latter nitrogen substituents optionally in the form of a basic nitrogen 30 functionality; as well as CO-R, COO-R, CONH-R, SO2-R, and SO2NH-R wherein R

is a linear or branched alkyl group containing from 1 to 10 carbon atoms and optionally substituted with at least one heteroatom, notably a halogen (selected from F, Cl, Br or I), oxygen, and nitrogen, the latter optionally in the form of a pendant basic nitrogen functionality.

5

R6 and R7 each independently are selected from:

- i) hydrogen, a halogen (selected from F, Cl, Br or I), or
- ii) an alkyl<sup>1</sup> group defined as a linear, branched or cycloalkyl group containing from 1 to 10 carbon atoms and optionally substituted with one or more heteroatoms such as halogen (selected from F, Cl, Br or I), oxygen, and nitrogen (the latter optionally in the form of a pendant basic nitrogen functionality); as well as trifluoromethyl, carboxyl, cyano, nitro, formyl; as well as CO-R, COO-R, CONH-R, SO<sub>2</sub>-R, and SO<sub>2</sub>NH-R wherein R is a linear or branched alkyl group containing 1 to 10 carbon atoms and optionally substituted with at least one heteroatom, notably a halogen (selected from F, Cl, Br or I), oxygen, and nitrogen, the latter optionally in the form of a pendant basic nitrogen functionality ; as well as a cycloalkyl or aryl or heteroaryl group optionally substituted by a pendant basic nitrogen functionality, or
- iii) an aryl<sup>1</sup> group defined as phenyl or a substituted variant thereof bearing any combination, at any one ring position, of one or more substituents such as
  - halogen(selected from I, F, Cl or Br);
  - an alkyl<sup>1</sup> group;
  - a cycloalkyl, aryl or heteroaryl group optionally substituted by a pendant basic nitrogen functionality;
  - trifluoromethyl, O-alkyl<sup>1</sup>, carboxyl, cyano, nitro, formyl, hydroxy, NH-alkyl<sup>1</sup>, N(alkyl<sup>1</sup>)(alkyl<sup>1</sup>), and amino, the latter nitrogen substituents optionally in the form of a basic nitrogen functionality;
  - NHCO-R or NHCOO-R or NHCONH-R or NHSO<sub>2</sub>-R or NHSO<sub>2</sub>NH-R or CO-R or COO-R or CONH-R or SO<sub>2</sub>-R or SO<sub>2</sub>NH-R wherein R corresponds to hydrogen, alkyl<sup>1</sup>, aryl or heteroaryl, or

(iv) a **heteroaryl<sup>1</sup>** group defined as a pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, thienyl, thiazolyl, imidazolyl, pyrazolyl, pyrrolyl, furanyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, indolyl, benzimidazole, quinolinyl group, which may additionally bear any combination, at any one ring position, of one or more substituents such as

- 5      - halogen (selected from F, Cl, Br or I);
- an **alkyl<sup>1</sup>** group;
- a cycloalkyl, aryl or heteroaryl group optionally substituted by a pendant basic nitrogen functionality,
- trifluoromethyl, O-alkyl<sup>1</sup>, carboxyl, cyano, nitro, formyl, hydroxy, NH-alkyl<sup>1</sup>, N(alkyl<sup>1</sup>)(alkyl<sup>1</sup>), and amino, the latter nitrogen substituents optionally in the form of a basic nitrogen functionality;
- 10     - NHCO-R or NHCOO-R or NHCONH-R or NHSO<sub>2</sub>-R or NHSO<sub>2</sub>NH-R or CO-R or COO-R or CONH-R or SO<sub>2</sub>-R or SO<sub>2</sub>NH-R wherein R corresponds to hydrogen, alkyl<sup>1</sup>, or
- 15     (v) an O-aryl<sup>1</sup>, or NH-aryl<sup>1</sup>, or O-heteroaryl<sup>1</sup> or NH-heteroaryl<sup>1</sup> group
- (vi) trifluoromethyl, O-alkyl<sup>1</sup>, carboxyl, cyano, nitro, formyl, hydroxy, NH-alkyl<sup>1</sup>, N(alkyl<sup>1</sup>)(alkyl<sup>1</sup>), and amino, the latter nitrogen substituents optionally in the form of a basic nitrogen functionality, or
- (vi) NHCO-R or NHCOO-R or NHCONH-R or NHSO<sub>2</sub>-R or NHSO<sub>2</sub>NH-R or CO-R
- 20     or COO-R or CONH-R or SO<sub>2</sub>-R or SO<sub>2</sub>NH-R wherein R corresponds to hydrogen, alkyl<sup>1</sup>, aryl or heteroaryl.

X is:


-NR<sub>9</sub>R<sub>10</sub>, wherein R<sub>9</sub> and / or R<sub>10</sub> are hydrogen or:

- 25     i) an **alkyl<sup>1</sup>** group, CF<sub>3</sub> or
- ii) an **aryl<sup>1</sup>**, **heteroaryl<sup>1</sup>** or **cycloalkyl** group optionally substituted by a a pendant basic nitrogen functionality, or
- iii) a CO-R, COO-R, CON-RR' or SO<sub>2</sub>-R, where R and R' are a hydrogen, alkyl<sup>1</sup>, aryl<sup>1</sup> or heteroaryl<sup>1</sup>, optionally substituted by a a pendant basic nitrogen functionality;
- 30     or:
- CO-NR<sub>9</sub>R<sub>10</sub>, wherein R<sub>9</sub> and / or R<sub>10</sub> are hydrogen or:

- i) an alkyl<sup>1</sup> group, CF<sub>3</sub> or
- ii) an aryl<sup>1</sup>, heteroaryl<sup>1</sup> or cycloalkyl group optionally substituted by a pendant basic nitrogen functionality.
- alkyl<sup>1</sup>

5

2. A compound according to claim 1 of formula I-2:




10

wherein R<sub>5</sub> = H, Y and Z represents an hydrogen, an aryl<sup>1</sup> or a heteroaryl<sup>1</sup> group, optionally substituted by a pendant basic nitrogen functionality and wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>6</sub>, and R<sub>7</sub> have the meaning as defined in claim 1.

15

3. A compound according to claim 1 of formula II :




### FORMULA II

20

Wherein Y is selected from O, S and Z corresponds to H, NR<sub>a</sub>R<sub>b</sub>, alkyl<sup>1</sup>, aryl<sup>1</sup>, O-alkyl<sup>1</sup>, or O-aryl<sup>1</sup> wherein Ra and Rb are independently chosen from H or alkyl<sup>1</sup> or aryl<sup>1</sup> or heteroaryl<sup>1</sup>, optionally substituted by a pendant basic nitrogen functionality and wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, and R<sub>7</sub> have the meaning as defined in claim 1.

4. A compound according to claim 3 of formula II-1:




5

**FORMULA II-1**

Wherein R5 = H, Y = O or S and Ra, Rb are independently chosen from H or alkyl<sup>1</sup> or aryl<sup>1</sup> or heteroaryl<sup>1</sup>, optionally substituted by a pendant basic nitrogen functionality and wherein R1, R2, R3, R4, R6, and R7 have the meaning as defined in claim 1.

5. A compound according to claim 4 of formula II-2:




15

**FORMULA II-2**

Wherein A is aryl<sup>1</sup> or heteroaryl<sup>1</sup> and wherein R1, R2, R3, R4, R6, R7, aryl<sup>1</sup>, heteroaryl<sup>1</sup> have the meaning described on pages as defined in claim 1.


6. A compound according to claim 4 of formula II-3:

**FORMULA II-3**

5 Wherein R is independently alkyl<sup>1</sup>, aryl<sup>1</sup> or heteroaryl<sup>1</sup> and wherein R1, R2, R3, R4, R5, R6, and R7 have the meaning described as defined in claim 1.

7. A compound according to claim 4 of formula II-4:


10

**FORMULA II-4**

Wherein R1, R2, R3, R4, R6, R7 and alkyl<sup>1</sup> have the meaning as defined in claim 1.

15


8. A compound according to claim 1 of formula I-3:



**FORMULA I-3**

Wherein R5 = H, X is  $\text{NHSO}_2\text{R}$  group, R is independently alkyl<sup>1</sup>, aryl<sup>1</sup> or heteroaryl<sup>1</sup> and wherein alkyl<sup>1</sup>, aryl<sup>1</sup>, heteroaryl<sup>1</sup>, R1, R2, R3, R4, R6 and R7 have the meaning  
5 as defined in claim 1.

9. A compound according to claim 1 of formula III:




10

**FORMULA III**

Wherein Y is selected from  $\text{NRaRb}$ ,  $\text{NHNRaRb}$ , alkyl<sup>1</sup>, aryl<sup>1</sup>, Ra wherein Ra and Rb are independently chosen from H or alkyl<sup>1</sup> or aryl<sup>1</sup> or heteroaryl<sup>1</sup>, optionally substituted by a pendant basic nitrogen functionality and wherein R1, R2, R3, R4, R6, and R7 have the meaning as defined in claim 1.  
15

10. A compound according to claim 1 of formula IV:



20

**FORMULA IV**

25

Wherein alkyl<sup>1</sup>, R1, R2, R3, R4, R6, and R7 have the meaning as defined in claim 1.

11. A compound as claimed in claim 1 selected from:

- 5     •4-{[4-Methyl-3-(4-pyridin-3-yl-oxazol-2-ylamino)-phenylamino]-methyl}-benzoic acid methyl ester;
- 4-Methyl-N1-(5-pyridin-3-yl-oxazol-2-yl)-N3-(5-pyridin-4-yl-oxazol-2-yl)-benzene-1,3-diamine;
- 4-Methyl-N1-(5-phenyl-oxazol-2-yl)-N3-(5-pyridin-4-yl-oxazol-2-yl)-benzene-1,3-diamine;
- 10     •4-Methyl-N1-(5-phenyl-[1,3,4]oxadiazol-2-yl)-N3-(5-pyridin-4-yl-oxazol-2-yl)-benzene-1,3-diamine;
- N1-Benzooxazol-2-yl-4-methyl-N3-(5-pyridin-4-yl-oxazol-2-yl)-benzene-1,3-diamine;
- 15     •N-[4-Methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-acetamide;
- 2-Cyano-N-[4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-acetamide;
- 2-Ethoxy-N-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-acetamide;
- 3-Methoxy-N-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-propionamide;
- 1-[4-Methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-3-p-tolyl-urea;
- 20     •1-(4-Cyano-phenyl)-3-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-urea;
- 1-(4-Fluoro-phenyl)-3-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-urea;
- 1-(2-Fluoro-phenyl)-3-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-urea;
- 1-[4-Methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-3-(4-trifluoromethyl-phenyl)-urea;
- 25     •1-(4-Chloro-phenyl)-3-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-urea;
- 1-[4-Methyl-3-(5-phenyl-oxazol-2-ylamino)-phenyl]-3-(3-trifluoromethyl-phenyl)-urea;
- 1-(4-Cyano-phenyl)-3-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-thiourea;

- 1-(4-Cyano-phenyl)-3-[4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-thiourea;
- (2-{2-Methyl-5-[3-(4-trifluoromethyl-phenyl)-ureido]-phenylamino}-oxazol-5-yl)-acetic acid ethyl ester;
- 5 •1-Benzyl-3-[4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-thiourea;
- 4-(4-Methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-benzamide;
- 3-Dimethylamino-N-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-benzamide;
- 10 •3-Bromo-N-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-benzamide;
- N-[4-Methoxy-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide;
- 4-(3-Dimethylamino-propylamino)-N-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide;
- 15 •N-[4-Fluoro-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide;
- 1*H*-Indole-6-carboxylic acid [4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-amide;
- 3-Isopropoxy-N-[4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-benzamide;
- 20 •N-[4-Methyl-3-(5-pyridin-2-yl-oxazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide;
- 3,5-Dimethoxy-N-[4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-benzamide;
- N-[3-(5-Pyridin-3-yl-oxazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide;
- 25 •N-[4-Methyl-3-(5-phenyl-oxazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide;
- 3-Fluoro-4-(4-methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-benzamide;
- N-[4-Chloro-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide;
- 30 •N-[4-Methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-terephthalamide;

- 5-Methyl-isoxazole-4-carboxylic acid [4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-amide;
- 4-Cyano-*N*-[4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-benzamide;
- *N*-[4-Methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-isonicotinamide;
- 5 • *N*-[4-Methyl-3-(4-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide;
- [4-Methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-carbamic acid isobutyl ester;
- (5-Isobutoxycarbonylamino-2-methyl-phenyl)-(5-pyridin-3-yl-oxazol-2-yl)-carbamic acid isobutyl ester;
- 10 • [4-Methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-carbamic acid isobutyl ester;
- *N*-[4-Methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-2-*m*-tolyl-acetamide;
- 2-(4-Fluoro-phenyl)-*N*-[4-methoxy-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-acetamide;
- 15 • 2-(2,4-Difluoro-phenyl)-*N*-[4-methyl-3-(5-phenyl-oxazol-2-ylamino)-phenyl]-acetamide;
- 2-(3-Bromo-phenyl)-*N*-[4-methyl-3-(5-pyridin-2-yl-oxazol-2-ylamino)-phenyl]-acetamide;
- 3-(4-Fluoro-phenyl)-*N*-[4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-propionamide;
- 20 • 2-(4-Fluoro-phenyl)-*N*-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-acetamide;
- *N*-{3-[5-(4-Cyano-phenyl)-oxazol-2-ylamino]-4-methyl-phenyl}-2-(2,4-difluoro-phenyl)-acetamide;
- 4-Methyl-pentanoic acid [4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-amide;
- 25 • *N*-[4-Methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-2-piperazin-1-yl-acetamide;
- *N*-[4-Methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-3-piperazin-1-yl-propionamide;

- 2-(2,6-Dichloro-phenyl)-N-[4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-acetamide;
- N-[4-Methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-3-pyrrolidin-1-yl-propionamide;
- 5 • N-[4-Methoxy-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-2-(4-trifluoromethyl-phenyl)-acetamide;
- 2-(4-Methoxy-phenyl)-N-[4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-acetamide;
- 10 • N-[4-Methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-C-phenyl-methanesulfonamide;
- N-(4-Cyano-phenyl)-4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-benzamide;
- N-(3-Dimethylamino-phenyl)-4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-benzamide;
- 15 • N-(2-Dimethylamino-ethyl)-4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-benzamide;
- N-(3-Fluoro-4-methyl-phenyl)-4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-benzamide;
- N-(3-Chloro-phenyl)-4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-benzamide;
- N-Benzyl-4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-benzamide;
- 20 • N-(4-Methoxy-benzyl)-4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-benzamide;
- [4-Methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-morpholin-4-yl-methanone;
- [4-Methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-piperazin-1-yl-methanone;
- 25 • N-(4-Fluoro-phenyl)-2-[4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-acetamide

12. A compound according to one of claims 1 to 10, wherein R6 is hydrogen and R7 is pyridyl, which may additionally bear any combination, at any one ring position, of one or more substituents such as

- 30 - halogen (selected from F, Cl, Br or I);
- an alkyl<sup>1</sup> group;
- an aryl<sup>1</sup> group;

- trifluoromethyl, O-alkyl<sup>1</sup>, carboxyl, cyano, nitro, formyl, hydroxy, NH-alkyl<sup>1</sup>, N(alkyl<sup>1</sup>)(alkyl<sup>1</sup>), and amino, the latter nitrogen substituents optionally in the form of a basic nitrogen functionality;
- NHCO-R or NHCOO-R or NHCONH-R or NSO<sub>2</sub>-R or NSO<sub>2</sub>NH-R or CO-R or COO-R or CONH-R or SO<sub>2</sub>-R or SO<sub>2</sub>NH-R wherein R corresponds to hydrogen, alkyl<sup>1</sup> or aryl<sup>1</sup> group.

5 13. A pharmaceutical composition comprising a compound according to one of claims 1 to 12.

10

14. A pharmaceutical composition according to claim 13 further comprising a pharmaceutically acceptable carrier.

15 15. A pharmaceutical composition according to claim 14 formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, and suspensions.

16. A cosmetic or pharmaceutical composition for topical administration comprising a compound according to one of claims 1 to 12.

20 17. Use of a compound according to one of claims 1 to 12 to manufacture a medicament.

25 18. Use of a compound according to one of claims 1 to 12 to manufacture a medicament for treating neoplastic diseases such as mastocytosis, canine mastocytoma, solid tumours, human gastrointestinal stromal tumor ("GIST"), small cell lung cancer, non-small cell lung cancer, acute myelocytic leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, myeloma 414, colorectal carcinomas, gastric carcinomas, badder gastrointestinal stromal tumors, testicular cancers, glioblastomas, astrocytomas, bladder cancer and 30 cancer in the airway tracts.

19. Use of a compound according to one of claims 1 to 12 to manufacture a medicament for treating allergic diseases such as asthma, allergic rhinitis, allergic sinusitis, anaphylactic syndrome, urticaria, angioedema, atopic dermatitis, allergic contact dermatitis, erythema nodosum, erythema multiforme, cutaneous necrotizing venulitis and insect bite skin inflammation and blood sucking parasitic infestation.
20. Use of a compound according to one of claims 1 to 12 to manufacture a medicament for treating inflammatory diseases such as rheumatoid arthritis, conjunctivitis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions.
21. Use of a compound according to one of claims 1 to 12 to manufacture a medicament for treating autoimmune diseases such as multiple sclerosis, psoriasis, intestine inflammatory disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis and polyarthritis, local and systemic scleroderma, systemic lupus erythematosus, discoid lupus erythematosus, cutaneous lupus, dermatomyositis, polymyositis, Sjogren's syndrome, nodular panarteritis, autoimmune enteropathy, as well as proliferative glomerulonephritis.
22. Use of a compound according to one of claims 1 to 12 to manufacture a medicament for treating graft-versus-host disease or graft rejection in any organ transplantation including kidney, pancreas, liver, heart, lung, and bone marrow.